A seismic shift is underway in how experts view functional recovery after a stroke.
For
years, the prevailing belief was that regaining limb mobility beyond 6
months was nearly impossible, as damaged brain circuits were thought to
be irreparable. But today, a wave of renewed optimism — fueled by
groundbreaking research — is challenging that notion. From brain
stimulation to stem cell therapy, scientists are exploring new ways to
push the boundaries of recovery.
It’s still early days, but the
potential impact of these emerging interventions could be profound.
Currently, approximately seven million Americans live with chronic
stroke, with an estimated 75% experiencing some level of impairment.
As
the population ages, stroke rehabilitation is poised to take center
stage. By 2050, the number of stroke survivors in the United States is
expected to nearly triple to 20 million, underscoring the urgent need for more effective recovery strategies.
Now,
a growing body of research is challenging long-held beliefs about the
limits of stroke recovery. Breakthroughs in neuroplasticity, brain
stimulation, and regenerative medicine are opening new doors — offering
fresh hope to patients and transforming stroke rehabilitation.
Brain Stimulation
Noninvasive
brain stimulation — such as transcranial direct current stimulation
(tDCS) or transcranial magnetic stimulation (TMS) — is being explored as
a way to enhance stroke recovery by pairing physical rehabilitation
with targeted brain stimulation to modulate disrupted neural networks.
However, key questions remain about the optimal dose, duration, and patient population. For example, findings from the TRANSPORT 2 trial,
presented at the International Stroke Conference (ISC) 2025, revealed
that tDCS, delivered at two different doses, did not improve upper
extremity function beyond the gains achieved through physical therapy
alone.
Despite the disappointing results from this relatively
small phase 2 trial, the research is far from over. “This doesn’t close
the door on tDCS,” said Lauren H. Sansing, MD, professor of neurology at
Yale School of Medicine, New Haven, Connecticut, and chair of ISC. “It
didn’t show a benefit, but it provided an enormous amount of data to
help us rethink how to test this therapy.”
Joseph Broderick, MD,
professor of neurology and rehabilitation medicine, University of
Cincinnati in Cincinnati and director of the UC Gardner Neuroscience
Institute, noted that determining the correct dose is essential as too
much stimulation “can cause side effects that you don’t want.”
In
addition, Wayne Feng, MD, professor of neurology and biomedical
engineering, Duke University School of Medicine, Durham, North Carolina,
who presented the TRANSPORT 2 results, acknowledged the lack of solid
evidence for tDCS but insisted “it has an edge over TMS. [tDCS] is
portable, easy to use, low cost, and can be paired with rehab therapy”
which can’t be said for TMS, he said.
Another noninvasive brain
stimulation technique, low-intensity transcranial focused ultrasound
stimulation, targets cortical, subcortical, and deep brain regions.
While
being explored for stroke recovery, it is also under investigation for a
range of other neurological and psychiatric conditions.
Researchers are also exploring more direct methods of neuromodulation.
Deep
brain stimulation (DBS) delivers constant electrical stimulation to a
particular brain region through a surgically implanted thin wire or
electrode.
One small trial
targeting the dentate nucleus in the cerebellum — an area involved in
coordinating muscle movements — showed that when combined with physical
therapy, the approach improved upper limb function in stroke patients
with persistent moderate to severe upper-extremity impairment.
Participants showed a median seven-point improvement on the
upper-extremity Fugl-Meyer scale.
Gary
K. Steinberg, MD, PhD, Lacroute-Hearst professor of neurosurgery and
neurosciences at Stanford University in California, believes electrical
brain stimulation will play a key role in poststroke rehabilitation.
Among the various approaches, he sees DBS as particularly promising.
However,
some experts caution that DBS is relatively invasive, requires
hospitalization, and carries potential neurosurgical risks.
Joel
Stein, MD, professor and chair, Department of Rehabilitation and
Regenerative Medicine, Columbia University, New York City, said he’s
somewhat skeptical about DBS. “I have found it’s hard to convince
patients to undergo a surgical intervention when the benefits may be
modest,” he told Medscape Medical News.
This hesitation around invasive procedures has led researchers to explore less invasive alternatives for stroke rehabilitation.
Vagus
nerve stimulation (VNS) has been shown to be safe and effective in
several neurological conditions, including epilepsy and stroke.
Following a positive phase 3 sham-controlled trial in 2021, the US Food
and Drug Administration approved a VNS device for patients in the
chronic stage of ischemic stroke (> 9 months poststroke) with
persistent moderate to severe upper extremity impairment.
Steinberg
emphasized the benefit is modest and noted VNS is only for upper limb
weakness, requires repeated stimulation, and has to be paired with
intensive rehabilitation.“Nomatter what form of energy you use to
stimulate the brain, whether it’s electrical or magnetic, the brain is
going to be a better target than the vagal nerve,” he said.
Some
experts argue that the precise mechanisms behind VNS and the
consistency of stimulation parameters in stroke treatment require
further investigation.
Exploring Stem Cell Therapy
This
ongoing need for refinement in neuromodulation therapies has also
driven interest in regenerative approaches, such as stem cell therapy.
Stem
cell therapy involves injecting human neural stem cells through a small
hole in the brain, a process designed to support neurorestoration.
These stem cells secrete powerful growth factors, along with other
proteins and molecules, that promote brain repair.(Use the correct word: exosomes!)
These factors
help neurons grow new axons and dendrites, stimulate the formation of
blood vessels in stroke-damaged areas, and reduce inflammation, all of
which contribute to the recovery process.
The first in-human phase
1/2a study, conducted by Steinberg and colleagues, enrolled 18 patients
at least 6 months poststroke but some years out from their stroke.
All
patients showed improvement in their total Fugl-Meyer motor score at 12
months, with 10 out of 16 achieving clinically meaningful recovery —
defined as an increase of 10 or more points on the scale.
Gains were observed in both upper and lower limb functions. Upper limb improvement at 12 months (+6.9; P
< .0002) exceeded that seen with VNS which showed an improvement of
only 5.3 points, according to Steinberg. He emphasized that this was
despite “our patients being much more severe” than those in the VNS
trial.
The intervention also improved gait, quality of life, and
even benefited patients with aphasia. Additionally, factors such as age,
gender, and stroke volume “didn’t matter” in terms of the extent of
improvement, Steinberg noted.
All adverse events, which included
incisional pain, nausea, and fatigue, resolved spontaneously and none
were related to the stem cells.
Steinberg and his colleagues are now planning a randomized multi-center, blinded study of stem cell therapy.
Broderick
cautioned that the study is too small to determine whether patients
would have improved without the intervention. He noted that many
treatments have generated excitement early on, only to show diminished
impact when tested in larger patient populations.
Stem cell
therapy has also been explored in Parkinson’s disease, a condition that
may be more suited to such an approach because it targets a specific
population of cells, Broderick noted. However, even in that context, “it
hasn’t worked out that well” and has been associated with side effects,
he added.
This uncertainty also extends to stroke treatment, where many fundamental questions remain unanswered.
Feng
emphasized the need to determine which cells should be injected or
infused, in what quantities, and which stroke patients are most likely
to benefit.
Robotics, Virtual Reality
As
researchers continue to refine biological interventions like stem cell
therapy, technological advancements are also playing a growing role in
stroke rehabilitation.
This fast-growing field involves using
robots or programmable devices designed to deliver high intensity
task-specific training. Growing evidence suggests robotic therapy can boost limb function and motivate patients to stick to rehab exercises.
This
is important as sustained repetitive exercises are crucial for
poststroke recovery, but many patients drop out due to cognitive and
other stroke-related issues.
However, Feng noted that research on
robotic therapy for severely impaired patients has been less than
encouraging, potentially highlighting the limits of brain plasticity.
“As much as we have fantasies about brain plasticity, it’s quite limited
in stroke patients once the brain has been ‘broken’ or injured by
stroke,” he said.
Despite these challenges, researchers continue
to explore alternative rehabilitation strategies. One emerging approach
is innovative virtual reality (VR) therapy, along with interactive video
gaming, which is gaining popularity as a neurorehabilitation modality.
A recent meta-review
of 57 systematic reviews, encompassing 1033 randomized controlled
trials, concluded that VR can improve upper and lower limb function,
balance, gait, and possibly cognition.
VR
offers several advantages over other rehabilitation approaches. It is
relatively affordable, enhances patient satisfaction and engagement, and
has no significant side effects.
“Exercise is a really critical
piece of recovery, but it’s very hard to get people to comply, so if you
can make it more engaging, that’s really important,” said Stein.
In
addition, VR is relatively accessible, using, for example, video games
offered by Nintendo Wii and Xbox Kinect. Some companies are attempting
to make games more stroke-specific, said Stein.
Broderick
pointed out that VR and other poststroke interventions do not address
deficits in language and vision caused by stroke. “There are limits to
what we can recover from,” he said.(Why are you giving up on 100% recovery?)
A variety of compounds —
including levodopa, fluoxetine, D-amphetamine, citicoline, niacin, and
inosine — are being tested in animal models and clinical trials or are
already in use to aid motor recovery after stroke. However, study
results have been mixed.
Lots more details in these for those looking to train their doctors! Look how long your doctor and hospital have been INCOMPETENT!
fluoxetine
(22 posts to May 2014)
Looking ahead, Broderick believes gene
therapy could eventually help “spark motor recovery” in some stroke
patients. He cited a study suggesting that certain genetic variants may
influence stroke recovery outcomes.